Xequel Bio acquired an exclusive, worldwide license from the Medical University of South Carolina (MUSC) for all fields of use for our pioneering technology platform, aCT1. Our strong partnership with MUSC has forged the way for an incredible breadth and depth of research into aCT1 and its varied potential applications.